中国医学创新2016，Vol.13Issue(29)：41-44,4.DOI:10.3969/j.issn.1674-4985.2016.29.011
沙利度胺联合环磷酰胺与地塞米松治疗复发难治多发性骨髓瘤
Thalidomide Combined with Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Refractory Multiple Myeloma
摘要
Abstract
Objective:To observe and study the clinical efficacy of Thalidomide combined with Cyclophosphamide and Dexamethasone in the treatment of recurrent refractory multiple myeloma.Method:From July 2013 and 2015 June in our hospital admissions difficult Zhido hair myeloma patients 50 cases,they were randomly divided into the control group(Bortezomib combined with Dexamethasone) and the observation group (Thalidomide combined with Cyclophosphamide and Dexamethasone),25 cases in each group,clinical effects and safety of two groups were compared.Result:The total efficiency rate of the observation group was 84.00%,compared with the control group,there was no statistical significance( χ²=2.58,P>0.05).The adverse reaction rate of the observation group was 12.00%,compared with the control group,there was statistical significance( χ²=4.32, P<0.05),all adverse reactions of patients were symptomatic treatment after a good recovery.The renal function recovery time and treatment time of the observation group were (18.49±3.20),(32.19±6.59)d,they were significantly lower than those of the control group(t=14.58,18.90,P<0.05).Medical cost of the observation group was lower than that of the control group(t=13.16,P<0.05).Conclusion:Thalidomide combined with Cyclophosphamide and Dexamethasonein the treatmeng of Relapsed refractory multiple myeloma have a clinical curative effect,can significantly improve the patient's symptoms,and in the course of treatment do not occur obvious adverse reaction, high security,with significance and value in clinical application.关键词
沙利度胺/环磷酰胺/地塞米松/复发难治多发性骨髓瘤Key words
Thalidomide/Cyclophosphamide/Dexamethasone/Relapsed refractory multiple myeloma引用本文复制引用
章志学,肖牛明,肖晓芳..沙利度胺联合环磷酰胺与地塞米松治疗复发难治多发性骨髓瘤[J].中国医学创新,2016,13(29):41-44,4.基金项目
2015年江西省卫生厅科研计划（普通）课题 （）
